论文部分内容阅读
目的:探讨符合线路18F-脱氧葡萄糖代谢显像(符合线路18F-FDG)在卵巢癌复发中的诊断价值。方法:对40例在核医学科接受符合线路18F-FDG显像的卵巢癌术后患者进行分析,并与CA125进行比较。结果:40例临床疑有复发的卵巢癌患者中,经临床或病理证实复发28例,24/28例符合线路18F-FDG显示阳性;22/28例血清CAI25升高。符合线路18F-FDG显像,CA125监测卵巢癌复发和转移的灵敏度、特异性和准确性分别为85.7%、66.7%和80%;78.6%、83.3%和80%。结论:符合线路18F-FDG显像作为无创伤性检查技术,能及时探测到复发或扩散肿瘤的代谢变化,可以为卵巢癌术后随访,特别是CA125升高的患者提供一种有效的非侵入性影像学诊断方法。
Objective: To investigate the diagnostic value of line 18F-FDG imaging (line 18F-FDG) in the recurrence of ovarian cancer. Methods: Forty patients with postoperative ovarian cancer who underwent 18F-FDG imaging in line with nuclear medicine were analyzed and compared with CA125. Results: Of the 40 patients with clinically suspected ovarian cancer who had clinically or pathologically confirmed recurrent tumors, 28 (28/28) were positive for 18F-FDG and 22 (28/28) were positive for CAI25. The sensitivity, specificity and accuracy of line 18F-FDG imaging and CA125 for the detection of ovarian cancer recurrence and metastasis were 85.7%, 66.7% and 80%, respectively; 78.6%, 83.3% and 80% respectively. CONCLUSION: Line 18F-FDG imaging as a noninvasive technique can detect the metabolic changes of recurrent or diffused tumors in time and provide an effective noninvasive method for postoperative follow-up of ovarian cancer, especially in patients with elevated CA125 Sexual imaging diagnosis method.